{"id":5634,"date":"2024-01-18T09:41:56","date_gmt":"2024-01-18T15:41:56","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5634"},"modified":"2025-06-27T11:24:42","modified_gmt":"2025-06-27T16:24:42","slug":"nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","title":{"rendered":"Nanoscope Therapeutics \u304c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u7528 MCO-010 \u306b\u95a2\u3059\u308b\u898f\u5236\u6700\u65b0\u60c5\u5831\u3092\u63d0\u4f9b"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<ul type=\"disc\">\n<li><strong><i>FDA\u3068EU\u898f\u5236\u5f53\u5c40\u306f\u3001\u8996\u529b\u304c\u5f31\u8996\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u306e\u6cbb\u7642\u306b\u304a\u3051\u308bMCO-010\u306e\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u6a5f\u80fd\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3068\u3044\u3046\u4e00\u8cab\u3057\u305f\u30a2\u30c9\u30d0\u30a4\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u308b<\/i><\/strong><\/li>\n<li><strong><i>\u898f\u5236\u5f53\u5c40\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u306b\u3088\u308a\u3001\u7c73\u56fd\u304a\u3088\u3073\u305d\u306e\u4ed6\u306e\u56fd\u3067\u306e\u627f\u8a8d\u306b\u81f3\u308b\u6f5c\u5728\u7684\u306a\u9053\u7b4b\u304c\u660e\u78ba\u306b\u306a\u308a\u307e\u3059\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>\u00a0RP \u306e MCO-010 \u7528\u3002 Nanoscope \u306f\u5373\u6642\u5b9f\u884c\u306b\u5411\u3051\u3066\u6e96\u5099\u4e2d<\/i><\/strong><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2024 \u5e74 1 \u6708 18 \u65e5<\/span><\/span> \u2014\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4071016-1&amp;h=2117084114&amp;u=https%3A%2F%2Fnanostherapeutics.com%2F&amp;a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u304a\u3088\u3073\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3059\u308b\u5f8c\u671f\u81e8\u5e8a\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u540c\u793e\u306f\u672c\u65e5\u3001\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08\u300cFDA\u300d\uff09\u3068\u306e\u6700\u8fd1\u306e\u898f\u5236\u306b\u95a2\u3059\u308b\u8b70\u8ad6\u304a\u3088\u3073Scientific Advice\u304b\u3089\u306e\u6700\u65b0\u60c5\u5831\u3092\u63d0\u4f9b\u3057\u307e\u3057\u305f\u3002 RP\u306e\u6cbb\u7642\u306b\u304a\u3051\u308bMCO-010\u306e\u898f\u5236\u306e\u65b9\u5411\u6027\u306b\u95a2\u3057\u3066\u3001\u30a2\u30a4\u30b9\u30e9\u30f3\u30c9\u533b\u85ac\u54c1\u5e81\uff08\u300cIMA\u300d\uff09\u3068\u306e\u4f1a\u5408\u3002<\/p>\n<p>FDA \u3068\u306e\u30bf\u30a4\u30d7 B \u30d5\u30a7\u30fc\u30ba 2 \u7d42\u4e86\u306b\u95a2\u3059\u308b\u751f\u7523\u7684\u306a\u8b70\u8ad6\u306b\u95a2\u9023\u3057\u3066\u3001Nanoscope \u306f\u3001\u9032\u884c\u6027 RP \u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306b\u304a\u3051\u308b MCO-010 \u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u95a2\u3059\u308b\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3092\u53d7\u3051\u53d6\u308a\u307e\u3057\u305f\u3002 FDA\u306f\u3001\u5f31\u8996\u60a3\u8005\u306e\u8996\u529b\u6e2c\u5b9a\u306b\u304a\u3051\u308b\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u304b\u3089\u306e\u5909\u5316\u306f\u3001\u9069\u5207\u304b\u3064\u3088\u304f\u7ba1\u7406\u3055\u308c\u305f\u7814\u7a76\u306b\u304a\u3051\u308b\u9069\u5207\u306a\u4e00\u6b21\u6709\u52b9\u6027\u8a55\u4fa1\u3068\u306a\u308a\u3001BLA\u306e\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u6709\u76ca\u6027\u306e\u5b9f\u8cea\u7684\u306a\u8a3c\u62e0\u3092\u63d0\u4f9b\u3067\u304d\u308b\u3068\u8ff0\u3079\u305f\u3002 MCO-010 \u306f\u3001FDA \u304b\u3089\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u3068\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u306e\u4e21\u65b9\u306e\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>Nanoscope \u306f\u3001MCO-010 \u306e\u627f\u8a8d\u30d7\u30ed\u30bb\u30b9\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001IMA \u3068\u306e\u79d1\u5b66\u7684\u30a2\u30c9\u30d0\u30a4\u30b9\u4f1a\u8b70\u304b\u3089\u3082\u80af\u5b9a\u7684\u306a\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u3092\u53d7\u3051\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>.<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA \u306f\u3001MCO-010 \u6cbb\u7642\u5f8c\u306e\u5f31\u8996 RP \u60a3\u8005\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306e\u9069\u5207\u306a\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u8996\u529b\u3092\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA\u306f\u307e\u305f\u30010.3 logMAR\u306e\u5909\u5316\u306f\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931RP\u60a3\u8005\u306b\u3068\u3063\u3066\u81e8\u5e8a\u7684\u306b\u610f\u5473\u304c\u3042\u308b\u3068\u652f\u6301\u3057\u305f\u3002<\/p>\n<p class=\"prnml40\" style=\"padding-left: 40px;\">IMA \u306f\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u304c MCO-010 \u306e\u6761\u4ef6\u4ed8\u304d\u627f\u8a8d\u3092\u691c\u8a0e\u3059\u308b\u3053\u3068\u3092\u63d0\u6848\u3057\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>\u00a0\u65e2\u5b58\u306e\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u898f\u5236\u5f53\u5c40\u306e\u8b70\u8ad6\u306b\u57fa\u3065\u3044\u3066\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306f\u9032\u884c\u4e2d\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u3001\u4e8c\u91cd\u30de\u30b9\u30af\u3001\u591a\u65bd\u8a2d\u30d5\u30a7\u30fc\u30ba\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u8996\u529b\u306b\u623b\u308a\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u52c9\u5f37\uff08\u5fa9\u5143\uff09\u3057\u307e\u3059\u3002\u7814\u7a76\u7d42\u4e86\u6642\u306e 100 \u9031\u9593\u30c7\u30fc\u30bf\u306f 2024 \u5e74\u4e0a\u534a\u671f\u306b\u5831\u544a\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u300c\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u8996\u529b\u304c\u6a5f\u80fd\u3059\u308b\u53ef\u80fd\u6027\u306b\u3064\u3044\u3066\u3001FDA \u3068 IMA \u306e\u4e21\u65b9\u304b\u3089\u4e00\u8cab\u3057\u305f\u610f\u898b\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u306f\u3001Nanscope \u306b\u3068\u3063\u3066\u5927\u304d\u306a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3067\u3042\u308a\u3001MCO-010 \u306b\u7c73\u56fd\u304a\u3088\u3073\u7c73\u56fd\u306b\u304a\u3051\u308b\u660e\u78ba\u306a\u898f\u5236\u306e\u9053\u7b4b\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002\u00a0<span class=\"xn-location\">\u30e8\u30fc\u30ed\u30c3\u30d1<\/span>\u3001&quot; \u8a00\u3063\u305f\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u5171\u540c\u5275\u8a2d\u8005\u517cCEO\u3002<\/p>\n<p><b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7 (RP) \u306f\u3001\u6642\u9593\u306e\u7d4c\u904e\u3068\u3068\u3082\u306b\u7db2\u819c\u306e\u5149\u53d7\u5bb9\u4f53\u7d30\u80de\u304c\u52a3\u5316\u3057\u3001\u8996\u529b\u969c\u5bb3\u3084\u6700\u7d42\u7684\u306b\u306f\u5931\u660e\u306b\u81f3\u308b\u4e00\u9023\u306e\u7a00\u306a\u907a\u4f1d\u6027\u75be\u60a3\u3092\u6307\u3057\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306f\u3001100 \u3092\u8d85\u3048\u308b\u7570\u306a\u308b\u907a\u4f1d\u5b50\u5909\u7570\u306b\u95a2\u9023\u3057\u3066\u3044\u308b\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u7d0410\u4e07\u4eba\u3001\u4e16\u754c\u4e2d\u3067\u306f\u63a8\u5b9a200\u4e07\u4eba\u304cRP\u306b\u82e6\u3057\u3093\u3067\u304a\u308a\u3001\u907a\u4f1d\u6027\u5931\u660e\u306e\u4e3b\u306a\u539f\u56e0\u3068\u306a\u3063\u3066\u3044\u308b\u3002<\/p>\n<p><b>MCO-010\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u73fe\u5728\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306f\u3001\u7279\u5b9a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u3092\u6301\u3064\u60a3\u8005\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u308b\u304c\u3001\u7db2\u819c\u5916\u5c64\u7d30\u80de\u304c\u5909\u6027\u3057\u305f\u9032\u884c\u6027\u75be\u60a3\u3067\u306f\u3055\u3089\u306b\u9650\u754c\u304c\u3042\u308b\u3002\u5468\u56f2\u5149\u3067\u6d3b\u6027\u5316\u53ef\u80fd\u306a MCO \u5149\u907a\u4f1d\u5b66\u7684\u5358\u72ec\u7642\u6cd5\u306f\u3001\u8c4a\u5bcc\u306a\u7db2\u819c\u5185\u30cb\u30e5\u30fc\u30ed\u30f3\u3092\u6a19\u7684\u3068\u3057\u3001\u9032\u884c\u3057\u305f RP \u306b\u3088\u308a\u6c38\u4e45\u306b\u5931\u308f\u308c\u305f\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 MCO-010 (sonpiretigene isteparvovec\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u7528\u61f8\u6fc1\u6db2) \u306f\u3001\u73fe\u5728\u81e8\u5e8a\u8a66\u9a13\u4e2d\u306e\u552f\u4e00\u306e\u5e83\u5e2f\u57df\u3001\u9ad8\u901f\u3001\u6700\u3082\u5149\u611f\u53d7\u6027\u306e\u9ad8\u3044\u30aa\u30d7\u30b7\u30f3\u3067\u3059\u3002 MCO-010 \u767a\u73fe\u30ab\u30bb\u30c3\u30c8\u306f\u3001mGluR6 \u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\u3092\u4ecb\u3057\u305f\u53cc\u6975\u7d30\u80de\u30bf\u30fc\u30b2\u30c6\u30a3\u30f3\u30b0\u3092\u5099\u3048\u3001\u73fe\u5b9f\u4e16\u754c\u306e\u74b0\u5883\u3067\u9ad8\u54c1\u8cea\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u72ec\u81ea\u306e AAV2 \u30d9\u30af\u30bf\u30fc\u306b\u3088\u308a\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u308b\u53cc\u6975\u7d30\u80de\u3078\u306e MCO-010 \u306e\u5f37\u529b\u306a\u5f62\u8cea\u5c0e\u5165\u304c\u53ef\u80fd\u306b\u306a\u308a\u307e\u3059\u3002\u9032\u884cRP\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u306e\u7b2c1\/2\u76f8\u8a66\u9a13\u3067\u306f\u3001\u826f\u597d\u306a\u5b89\u5168\u6027\u3068\u7528\u91cf\u4f9d\u5b58\u7684\u306a\u8996\u529b\u306e\u6539\u5584\u304c\u5b9f\u8a3c\u3055\u308c\u307e\u3057\u305f\u3002 MCO-010\u6cbb\u7642\u3092\u53d7\u3051\u305f\u60a3\u8005\u3067\u306f\u3001\u5bfe\u7167\u7fa4\u3068\u6bd4\u8f03\u3057\u3066\u3001\u540d\u76ee\u4e0a\u6709\u610f\u306a\u8996\u529b\u306e\u6539\u5584\u304c\u89b3\u5bdf\u3055\u308c\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u5fa9\u5143\u30c8\u30e9\u30a4\u30a2\u30eb\u3002\u307e\u305f\u3001\u591a\u8f1d\u5ea6\u8996\u899a\u306b\u57fa\u3065\u304f\u53ef\u52d5\u6027\u3068\u5f62\u72b6\u8b58\u5225\u306b\u3088\u3063\u3066\u8a55\u4fa1\u3055\u308c\u308b\u3088\u3046\u306b\u3001\u540d\u76ee\u4e0a\u5927\u5e45\u306a\u6a5f\u80fd\u7684\u8996\u899a\u306e\u6539\u5584\u304c\u898b\u3089\u308c\u3001\u597d\u307e\u3057\u3044\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3082\u5f97\u3089\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics \u306f\u3001\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u306b\u3088\u3063\u3066\u5931\u660e\u3057\u305f\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u305b\u305a\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306e\u4e3b\u8981\u8cc7\u7523\u3067\u3042\u308b MCO-010 \u306f\u6700\u8fd1\u3001RESTORE \u30d5\u30a7\u30fc\u30ba\u306e\u30c8\u30c3\u30d7\u30e9\u30a4\u30f3\u7d50\u679c\u3092\u5831\u544a\u3057\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u7c73\u56fd\u306b\u304a\u3051\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u30de\u30b9\u30af\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4071016-1&amp;h=1764809894&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D517760235%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&amp;a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3002\u540c\u793e\u306f\u6700\u8fd1\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f MCO-010 \u7642\u6cd5\u306e\u7b2c 2 \u76f8 STARLIGHT \u8a66\u9a13\u3082\u5b8c\u4e86\u3057\u307e\u3057\u305f (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4071016-1&amp;h=831375813&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3984630-1%2526h%253D1090222651%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT05417126%25253Fterm%25253Dnanoscope%252526draw%25253D2%252526rank%25253D3%2526a%253DNCT05417126%26a%3DNCT05417126&amp;a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0\uff09\u3002 MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3068\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u306b\u5bfe\u3057\u3066FDA\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u304a\u3088\u3073FDA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001\u5730\u7406\u7684\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u30ec\u30fc\u30b6\u30fc\u306b\u3088\u308b MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patients Regulatory feedback provides clarity for potential path to approval in the US and in\u00a0Europe\u00a0for MCO-010 in RP; Nanoscope preparing for immediate execution DALLAS,\u00a0Jan. 18, 2024 &#8212;\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and from the Scientific Advice meeting with the Icelandic Medicines Agency (&#8220;IMA&#8221;), regarding the regulatory path of MCO-010 for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5635,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-18T15:41:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa\",\"datePublished\":\"2024-01-18T15:41:56+00:00\",\"dateModified\":\"2025-06-27T16:24:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"wordCount\":722,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"datePublished\":\"2024-01-18T15:41:56+00:00\",\"dateModified\":\"2025-06-27T16:24:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/NSCOPE_LI_regulatory-update.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/01\\\/18\\\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306b\u95a2\u3059\u308b\u898f\u5236\u5f53\u5c40\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-01-18T15:41:56+00:00","article_modified_time":"2025-06-27T16:24:42+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa","datePublished":"2024-01-18T15:41:56+00:00","dateModified":"2025-06-27T16:24:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"},"wordCount":722,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306b\u95a2\u3059\u308b\u898f\u5236\u5f53\u5c40\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","datePublished":"2024-01-18T15:41:56+00:00","dateModified":"2025-06-27T16:24:42+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/01\/NSCOPE_LI_regulatory-update.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/01\/18\/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5634"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634\/revisions"}],"predecessor-version":[{"id":9058,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5634\/revisions\/9058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5635"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}